Cost-effectiveness analysis of penpulimab plus carboplatin-paclitaxel as first-line treatment for metastatic squamous non-small-cell lung cancer in China
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-07-30 10:04:49 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1186/s13561-025-00656-1
文献链接: https://healtheconomicsreview.biomedcentral.com/articles/10.1186/s13561-025-00656-1
其他信息:
出版社: Springer Science and Business Media LLC
作者: Luwei Wang; Jiasheng Chen; Lihui Lin; Xiaowei Huang
全文下载地址: https://link.springer.com/content/pdf/10.1186/s13561-025-00656-1.pdf